The breast is the most frequent site of cancer among women in both developed and in developing countries [1]. Breast cancer is the most frequent cause of cancer death in women from less developed countries and second most frequent (after lung cancer) among women in developed countries [1]. It is increasing in incidence in the developing world due to increased life expectancy, increased urbanization and the adoption of western lifestyles [2]. According to the World Health Organization (WHO), “Early detection in order to improve breast cancer outcome and survival remains the cornerstone of breast cancer control” [2]. Breast cancer staging also takes into account cancer's grade; the presence of tumor markers, such as receptors for estrogen, progesterone and HER2; and proliferation factors.Standard screening for new and recurrent breast cancer involves clinical breast exam and breast imaging. Given the recognized differences in breast cancer incidence, subtypes, and prognosis among women , it is important to evaluate potential biomarkers in the landscape of breast cancer subtypes ranging from DCIS to triple-negative breast cancer (TNBC) to determine if a simple blood test can enhance the diagnosis of this disease and knowing about stage of disease, and helping in proper treatment. In this review we tried to discuss role of genetic panels in breast cancer management